

PCR-/NAT VRE (RV 546) Nov 2025



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected	Probenzusammensetzung / Sample composition
546A 251014 01	+++	61 / 71 <i>E. faecium</i> vanA (~ 2x10 ⁵ CFU/mL)
546A 251014 02	++	61 / 72 <i>E. faecium</i> vanB (~ 5x10 ⁴ CFU/mL)
546A 251014 03	Ø	62 <i>Escherichia coli</i> K12
546A 251014 04	++	61 / 71 <i>Enterococcus faecalis</i> vanA (~ 5x10 ⁴ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 69		Proben Nr. (Sample no.)				Inhibition				
Befund Result		01	02	03	04		01	02	03	04
Positiv	69	66	0	68		n.d.	1	1	1	1
Negativ	0	3	69	1		nein no	68	68	68	68
Fraglich Questionable	0	0	0	0		ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv True positive results						NAT richtig negativ	
	01		02		04		03	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
Amplex eazyplex VRE (n = 4)	4	100	4	100	4	100	4	100
Amplex eazyplex VREbasic (n = 8)	8	100	5	63	7	88	8	100
AmpliGnost Vancomycin A/B (n = 3)	3	100	3	100	3	100	3	100
BioGx Vancomycin resistance (n = 2)	2	100	2	100	2	100	2	100
Bruker-HAIN GenoType Enterococcus (n = 4)	4	100	4	100	4	100	4	100
Cepheid Xpert vanA / vanB (n = 25)	25	100	25	100	25	100	25	100
ampliCube MDR Panel 6 (n = 2)	2	100	2	100	2	100	2	100

Seegene Allplex Entero-DR (n = 10)	10	100	10	100	10	100	10	100
TIB Molbiol LightMix Kits (n = 2)	2	100	2	100	2	100	2	100
<i>In house</i> PCR assay (n = 9)	9	100	9	100	9	100	9	100

Comments:

1. Sixty-seven participants reported dedicated vanA / vanB identification. Except one laboratory, all reported results were correct